Country: United States
Language: English
Source: NLM (National Library of Medicine)
MORPHINE SULFATE (UNII: X3P646A2J0) (MORPHINE - UNII:76I7G6D29C)
Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC
MORPHINE SULFATE
MORPHINE SULFATE 30 mg
ORAL
PRESCRIPTION DRUG
Morphine sulfate tablets contain morphine, an opioid analgesic, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. Morphine sulfate is contraindicated in patients with known hypersensitivity to morphine, morphine salts, or any components of the product. Morphine sulfate is contraindicated in patients with respiratory depression in the absence of resuscitative equipment. Morphine sulfate is contraindicated in patients with acute or severe bronchial asthma or hypercarbia. Morphine sulfate is contraindicated in any patient who has or is suspected of having paralytic ileus. Animal reproduction studies have not been conducted with morphine sulfate. It is also not known whether morphine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Only give morphine sulfate to a pregnant woman if clearly needed. In humans, the frequency of congenital anomalies has been reported to be no greater than expecte
Morphine Sulfate Tablets 15 mg Tablet: white, biconvex tablets scored on one side and product identification "54 733" debossed on the other side. Unit dose, 25 tablets per card NDC 0054-0235-24: 4 Cards Per Carton NDC 0054-0235-25: Bottle of 100 Tablets 30 mg Tablet: white, biconvex tablets scored on one side and product identification "54 262" debossed on the other side. Unit dose, 25 tablets per card NDC 0054-0236-24: 4 Cards Per Carton NDC 0054-0236-25: Bottle of 100 Tablets Storage Store at Controlled Room Temperature, 15° to 30°C (59° to 86°F). PROTECT FROM MOISTURE. All opioids are liable to diversion and misuse both by the general public and healthcare workers and should be handled accordingly.
New Drug Application
Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC ---------- MEDICATION GUIDE Revised: 1/2021 Document Id: 5d265270-9d04-4017-9753-f2abb9130b4a 34391-3 Set id: d9a4179d-b21d-4921-be29-089ecfcb6e6a Version: 3376 Effective Time: 20210129 Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC Read the complete document
MORPHINE SULFATE- MORPHINE SULFATE TABLET LAKE ERIE MEDICAL & SURGICAL SUPPLY DBA QUALITY CARE PRODUCTS LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE MORPHINE SULFATE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR MORPHINE SULFATE TABLETS. MORPHINE SULFATE TABLETS, CII INITIAL U.S. APPROVAL: 1984 INDICATIONS AND USAGE Morphine sulfate is an opioid analgesic indicated for the relief of moderate to severe acute and chronic pain where an opioid analgesic is appropriate. (1) DOSAGE AND ADMINISTRATION Morphine Sulfate Tablets: 15 to 30 mg every 4 hours as needed. (2.2) DOSAGE FORMS AND STRENGTHS Tablets: 15 mg or 30 mg. (3) CONTRAINDICATIONS Known hypersensitivity to morphine. (4) Respiratory depression in the absence of resuscitative equipment. (4) Acute or severe bronchial asthma or hypercarbia. (4) Paralytic ileus. (4) WARNINGS AND PRECAUTIONS Respiratory depression: Increased risk in elderly, debilitated patients, those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction. (5.1) Controlled substance: Morphine sulfate is a Schedule II controlled substance with an abuse liability similar to other opioids. (5.2) CNS effects: Additive CNS depressive effects when used in conjunction with alcohol, other opioids, or illicit drugs. (5.3) Elevation of intracranial pressure: May be markedly exaggerated in the presence of head injury, other intracranial lesions. (5.4) Hypotensive effect: Increased risk with compromised ability to maintain blood pressure. (5.5) Prolonged gastric obstruction: In patients with gastrointestinal obstruction, especially paralytic ileus. (5.6) Sphincter of Oddi spasm and diminished biliary/pancreatic secretions. Increased risk with biliary tract disease. (5.7) Special Risk Groups: Use with caution and in reduced dosages in patients with severe renal or hepatic impairment, Addison's disease, hypothyroidism, prostatic hypertrophy, or urethral stricture, elderly, CNS dep Read the complete document